| Yevheniy Lider, MD | |
|
3000 Hospital Blvd, Roswell, GA 30076-4915 | |
| (770) 751-2500 | |
| Not Available |
| Full Name | Yevheniy Lider |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 9 Years |
| Location | 3000 Hospital Blvd, Roswell, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033593629 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 79977 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wellstar North Fulton Hospital | Roswell, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North Fulton Emergency Physicians, Llc | 6800981986 | 8 |
News Archive
On Thursday, September 19th, 2019, the Physicians Committee for Responsible Medicine hosted a congressional briefing in cooperation with Rep. Brendan Boyle (D-Pa.), featuring innovator companies showcasing cutting-edge technologies that have the potential to improve the safety and efficacy of pharmaceuticals while reducing animal testing.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
Manual-therapy randomized controlled trials (RCTs) are difficult to perform because it's challenging to conceal a placebo when patients are able to physically feel a treatment that's being delivered.
Our research focuses on interleukin 1 and the inflammasome and their role in innate immunity and inflammation.
› Verified 9 days ago
| Entity Name | North Fulton Emergency Physicians, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053456954 PECOS PAC ID: 6800981986 Enrollment ID: O20071004000272 |
News Archive
On Thursday, September 19th, 2019, the Physicians Committee for Responsible Medicine hosted a congressional briefing in cooperation with Rep. Brendan Boyle (D-Pa.), featuring innovator companies showcasing cutting-edge technologies that have the potential to improve the safety and efficacy of pharmaceuticals while reducing animal testing.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
Manual-therapy randomized controlled trials (RCTs) are difficult to perform because it's challenging to conceal a placebo when patients are able to physically feel a treatment that's being delivered.
Our research focuses on interleukin 1 and the inflammasome and their role in innate immunity and inflammation.
› Verified 9 days ago
| Entity Name | Emergency Physicians Of Forsyth, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518488618 PECOS PAC ID: 1850663626 Enrollment ID: O20170815001575 |
News Archive
On Thursday, September 19th, 2019, the Physicians Committee for Responsible Medicine hosted a congressional briefing in cooperation with Rep. Brendan Boyle (D-Pa.), featuring innovator companies showcasing cutting-edge technologies that have the potential to improve the safety and efficacy of pharmaceuticals while reducing animal testing.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
Manual-therapy randomized controlled trials (RCTs) are difficult to perform because it's challenging to conceal a placebo when patients are able to physically feel a treatment that's being delivered.
Our research focuses on interleukin 1 and the inflammasome and their role in innate immunity and inflammation.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Yevheniy Lider, MD 5665 New Northside Dr Ste 320, Atlanta, GA 30328-5834 Ph: (404) 265-4450 | Yevheniy Lider, MD 3000 Hospital Blvd, Roswell, GA 30076-4915 Ph: (770) 751-2500 |
News Archive
On Thursday, September 19th, 2019, the Physicians Committee for Responsible Medicine hosted a congressional briefing in cooperation with Rep. Brendan Boyle (D-Pa.), featuring innovator companies showcasing cutting-edge technologies that have the potential to improve the safety and efficacy of pharmaceuticals while reducing animal testing.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
Manual-therapy randomized controlled trials (RCTs) are difficult to perform because it's challenging to conceal a placebo when patients are able to physically feel a treatment that's being delivered.
Our research focuses on interleukin 1 and the inflammasome and their role in innate immunity and inflammation.
› Verified 9 days ago
Michael Lipscomb, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3000 Hospital Blvd, Roswell, GA 30076 Phone: 770-751-2567 | |
Damon C. Kimes, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1300 Upper Hembree Rd Ste B, Roswell, GA 30076 Phone: 678-736-7680 Fax: 888-537-5362 | |
Samuel Lorenzo, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1360 Upper Hembree Rd, Suite 100, Roswell, GA 30076 Phone: 678-672-5100 Fax: 678-672-5101 | |
Charles V Pollack Jr., MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1120 Wilde Run Ct, Roswell, GA 30075 Phone: 610-329-2986 Fax: 888-959-8345 | |
Dr. Lisa M Perez, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 303 Bombay Ln, Roswell, GA 30076 Phone: 678-869-5158 Fax: 678-869-5159 | |
Jonathan Mills, Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 3000 Hospital Blvd, Roswell, GA 30076 Phone: 770-751-2567 |